Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About GPC Biotech

GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. GPC Biotech's lead product candidate -- satraplatin -- has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has completed the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and its wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at http://www.gpc-biotech.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or im
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/17/2014)... discovering a new mechanism that allows blood to enter ... Irvine and the Salk Institute have opened the door ... brain damage. , A complex and devastating neurological condition, ... reason for disability in the U.S. The blood-brain barrier ... material into the brain, causing the permanent deficits in ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
(Date:4/17/2014)... and their partners have found that their proprietary microbicide ... of multiple sexually transmitted infections (STIs) in both the ... 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study ... effective against multiple strains of HIV, and has a ... viruses of at least eight hours prior to exposure. ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... in Sudan Called "Ground-breaking", DUBAI, United Arab ... billion last fall in an 8-week fundraising drive,Dubai ... the recipients of,its Phase One funding. Dubai Cares ... to improving primary education for,children in developing countries., ...
... of Energy,s Brookhaven National Laboratory have shown that increasing ... chemical, can reduce use of cocaine by 75 percent ... this team had similar findings for alcohol intake. Treatments ... receptors -- may prove useful in treating addiction, according ...
... supports hundreds of programs helping millions in the,developing ... WASHINGTON, April 16 The worldwide,pharmaceutical industry today ... biopharmaceutical companies, global,health leaders and policymakers together to ... developing world., Serving as a convening point ...
... The early use of magnetic resonance imaging (MRI) in ... a better adapted surgical approach to the tumour, a ... today (Wednesday April 16). Dr. David Martinez-Cecilia, a ... Rufian-Pea, in the Hospital Universitario Reina Sofia, Cordoba, Spain, ...
... 15 ECO2 Plastics, Inc.,(OTC Bulletin Board: ECOO), ... plastics are recycled, today reported its 2007 year-end,financial ... revenues of,$4.3 million for calendar year 2007 versus ... versus $14.9 million during the prior,year, with net ...
... to clamp the umbilical cord after a baby is born could ... comes with an increased risk of jaundice, according to a new ... seconds after birth is one of three steps in an active ... a new mother is vulnerable to excessive blood loss. Studies show ...
Cached Medicine News:Health News:Dubai Cares Announces 12 Country Plan to Educate and Empower Children in Developing Nations 2Health News:Dubai Cares Announces 12 Country Plan to Educate and Empower Children in Developing Nations 3Health News:Dubai Cares Announces 12 Country Plan to Educate and Empower Children in Developing Nations 4Health News:Gene therapy reduces cocaine use in rats 2Health News:Worldwide Pharmaceutical Industry Launches Global Health Progress Initiative to Expand Efforts to Improve Health in Developing Countries 2Health News:Worldwide Pharmaceutical Industry Launches Global Health Progress Initiative to Expand Efforts to Improve Health in Developing Countries 3Health News:MRI before surgery leads to better-adapted treatment for breast cancer 2Health News:ECO2 Plastics, Inc. Reports 2007 Year End Financial Results, Announces FDA Filing and Provides Outlook for 2008 2Health News:ECO2 Plastics, Inc. Reports 2007 Year End Financial Results, Announces FDA Filing and Provides Outlook for 2008 3Health News:Health risks, benefits come with delayed umbilical cord clamping 2
Rigid rake retractor, 3 blunt prongs....
Econo lucae bayonet forceps....
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
... Inferior Orbital Rim implant can provide up ... designed to be trimmed to meet the ... flange allows it to rest on the ... This flange allows easier positioning of the ...
Medicine Products: